▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Motley Fool Staff

the_motley_fool

Recent Articles by Motley Fool Staff

Jun 13, 2016 by Motley Fool Staff

Should You Convert Your IRA to a Roth?

If you want the tax-free benefits of a Roth IRA, you can get them by converting an existing traditional IRA. Find out the details here.

Jun 12, 2016 by Motley Fool Staff

How Your Heirs Can Inherit Your IRA

IRAs are designed for your retirement, but many people die before using up all of their retirement savings. Find out what your heirs need to do in order to reap the benefits of your financial foresight.

Jun 12, 2016 by Motley Fool Staff

Is Biogen a Buy After its Clinical Failure?

A key trial of a once-promising multiple sclerosis drug came up short, but investors should listen to this debate before buying or selling.

Jun 11, 2016 by Motley Fool Staff

AbbVie's Rova-T Update at ASCO: Good or Bad?

A presentation for Rova-T in small cell lung cancer failed to excite investors, but that could change.

Jun 11, 2016 by Motley Fool Staff

What Counts as Earned Income for an IRA?

There are requirements to set up tax-favored retirement accounts. Find out what they are and whether you and your family members can qualify to set up an IRA.

Jun 10, 2016 by Motley Fool Staff

Traditional or Roth IRA: Which Should You Pick?

Choosing between the two main types of tax-favored retirement accounts can be tough. Find out what you need to know in order to make a smart choice.

Jun 10, 2016 by Motley Fool Staff

Immunomedics' ASCO Letdown

A surprise cancellation of its presentation at ASCO caused Immunomedics shares to plummet last week.

Jun 10, 2016 by Motley Fool Staff

Traditional vs. Roth: 2 IRAs Everyone Should Consider

If you've ever thought about using an individual retirement account to save for your golden years, you need to know about the two different types of IRAs available to you. Get the basics here.

Jun 10, 2016 by Motley Fool Staff

What IRAs Offer That Savings Accounts Don't

Many people hesitate to lock up their retirement savings in an IRA, but the advantages outweigh the disadvantages. Find out more about the benefits of IRAs.

Nov 1, 2016 by Motley Fool Staff

How to Calculate the Interest Rates on Perpetuity

Here's how to calculate the interest rate on a perpetuity with a helpful example.

Jun 9, 2016 by Motley Fool Staff

What Investors Should Know About Brazilian Oil

Why the five-year charts are trending hugely down and what long-term investors should know about buying in now.

Jun 8, 2016 by Motley Fool Staff

Should You Try to Buy Stocks That Billionaires Buy?

You can read the 13F filings of ultra-rich investors to see what was in their portfolios, which gives you a way to attempt to ride their stock picking coattails. But there are a couple of big flaws with that strategy.

Jun 8, 2016 by Motley Fool Staff

What a Possible Trump Presidency Means for the Oil Industry

Here's what Donald Trump is saying and promising about the sector.

Jun 8, 2016 by Motley Fool Staff

What the Lowest Levels of Oil Discovery in 6 Decades Means for Investors

What it means for the world that last year clocked the lowest oil finds since 1952.

Jun 7, 2016 by Motley Fool Staff, Chris Hill, Matthew Argersinger, and Steve Broido

The Golden Age of TV Is Golden for Lions Gate

Movies are a weak point.

Jun 7, 2016 by Motley Fool Staff

Carl Icahn Bets Big on Allergan's CEO

Carl Icahn's took his "large" new stake in Allergan based on his opinion that CEO Brenton Saunders could make him a profit for a second time. Exactly how? That's still not so clear.

Jun 6, 2016 by Motley Fool Staff

The Bayer-Monsanto Merger That Probably Won't Happen (Thankfully)

How one company could own 30% of the world's agricultural seed market, and why it probably won’t.

Jun 6, 2016 by Motley Fool Staff

Red Bull Is Not GoPro's Knight in Shining Armor

One analyst calls this GoPro's "Jump the Shark" moment, predicting it's all downhill from here.

Jun 6, 2016 by Motley Fool Staff

What's George Soros Telling Us About Buying Biotech?

Billionaire guru George Soros made an intriguing biotech buy last quarter.

Jun 6, 2016 by Motley Fool Staff

3 Stocks on Our Radar

Why we’re interested in Modine Manufacturing, Starbucks, and Celgene.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services